Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
Investors, after facing huge losses amid the threat of the coronavirus, are grappling with what is next for the stock market. In January, I warned that an external event could cause a major drop in the market. Now it has happened. Something investors need to be on the lookout for: potential treatments
These posts were published on ZYX Short Sell Change Alert. The short zone for Acorda Therapeutics (ACOR) is $24.50 to $26.40. Since the stock is moving fast we want to get this to you quickly. We will do another post shortly with more details. Maximum position size is 30% of full core
Dividend-chasing is in vogue. Given low interest rates, many investors say they have no other choice. Such thinking leads to costly mistakes. It just badly hurt those who had bought shares of Teva Pharmaceutical Industries TEVA, because of its high dividend yield. This isn’t just an issue for Teva investors,
Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan keeps the basic framework of Obamacare. No wonder some are calling it “Obamacare Lite.”
This post was just published on ZYX Buy Change Alert. MYL is long from an average price of $37.78. As of this writing it is trading at $41.97. Consider taking profits on a 15% tranche in the zone of $41.23 to $44.73. Consider a stop on the remaining in the zone of
This post was published on ZYX Buy Change Alert. MNTA has an average price of $11.31. As of this writing it is trading at $19.05. The stock has jumped on a court invalidating TEVA patent on a MS drug Copaxone. This was part of the original thesis to buy MNTA. MYL is
This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug. The new buy zone is $32 to $35.57. Recommended position size is 35% to 40%. The stock is trading at $38.40 as of this writing. What To Do Now
This post was published on ZYX Buy Change Alert. Consider reducing MYL position to 30% of the full core position size if holding a larger position. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click